Table 6 Cox regression analysis of factors associated with overall survival in included COVID-19 cases in the study (n = 439)
From: Comorbidities and outcomes among patients hospitalized with COVID-19 in Upper Egypt
Factors | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
HR (95% CI) | P-value | HR (95% CI) | P-value | |
Age group (Ref. = 18–39) | ||||
40–59 | 1.9 (0.89–3.8) | 0.097 | 1.8 (0.81–3.9) | 0.151 |
60–79 | 3.9 (2.0–7.8) | < 0.001^ | 3.7 (1.6–8.4) | 0.002 |
> 80 | 10.1 (4.0–25.6) | < 0.001^ | 8.0 (2.7–24.0) | < 0.001 |
Gender (Ref. = Female) | ||||
Male | 1.2 (0.71–1.6) | 0.737 | – | – |
DM | 1.3 (0.86–1.9) | 0.211 | – | – |
CVD | 1.9 (1.2–2.8) | 0.003^ | 0.81 (0.41–1.6) | 0.542 |
Chronic pulmonary | 0.93 (0.43–2.0) | 0.859 | – | – |
Neuropsychiatric disease | 2.9 (1.5–5.6) | 0.002^ | 2.2 (1.1–4.7) | 0.031 |
Kidney disease | 1.7 (0.78–3.7) | 0.184 | – | – |
Liver disease | 1.4 (0.55–3.4) | 0.502 | – | – |
Metabolic and endocrinal | 0.74 (0.18–3.0) | 0.672 | – | – |
Autoimmune disease | 1.1 (0.27–4.4) | 0.909 | – | – |
Number of comorbidities | ||||
1 | 2.0 (1.1–3.7) | 0.023^ | 1.3 (0.63–2.6) | 0.496 |
2 | 2.6 (1.4–4.7) | 0.002^ | 1.5 (0.61–3.5) | 0.396 |
≥ 3 | 2.9 (1.5–5.6) | 0.001^ | 1.3 (0.49–3.7) | 0.564 |